Metabolism of Omega-3 and Omega-6 During Healthy Aging

Overview

The purpose of this study is to determine the kinetics of 13C-eicosapentaenoic acid (EPA) and 13C-arachidonic acid (AA) in young and older participants

Full Title of Study: “Metabolism of Uniformly Labelled 13C Eicosapentaenoic Acid and 13C Arachidonic Acid During Healthy Aging”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: July 2016

Interventions

  • Other: 13C eicosapentaenoic acid and 13C arachidonic acid
    • Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.

Arms, Groups and Cohorts

  • Young
    • Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
  • Elderly
    • Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.

Clinical Trial Outcome Measures

Primary Measures

  • Kinetics of 13C-EPA and 13C-AA
    • Time Frame: Plasma incorporation of 13C-EPA or 13C-AA was measured from the area under the curve in young and older participants over 28 days post-dose

Participating in This Clinical Trial

Inclusion Criteria

  • six young (18-30 y old) and six older (≥ 70 y old) – healthy non medicated participants. Exclusion Criteria:

  • Tobacco, – malnutrition (assessed from blood albumin, haemoglobin and lipids), - – participants taking an EPA+DHA supplements or consuming more than 2 fish meals per week, – severe gastro-intestinal problems, – medication for diabetes, – thyroid disease, – renal failure, – cancer, – psychiatric difficulties or depression, – cardiovascular disease, – glucose intolerance (>8 mmol/L in fasted samples) – chronic immune condition or inflammation (CRP > 10 mg/l, white cell count), – recent major surgery or cardiac event, – dementia, – ongoing or past severe drug or alcohol abuse, – ongoing or past intensive physical training.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Université de Sherbrooke
  • Collaborator
    • Healthy Aging Research Network
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mélanie Plourde, Professor – Université de Sherbrooke

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.